Showing results (241-250 of 523) with videos related to

Sort By:
Pageof 53
Clinical and Experimental Immunology|September 8, 2025
Expanded senescent CD8 T cells in IMID patients are associated with distinct inflammatory cytokinesMarie Naigeon, Samuel Bitoun, Matthieu Roulleaux Dugage, et al.
Journal of the National Cancer Institute|April 10, 2025
Neoadjuvant versus perioperative chemo-immunotherapy according to pathological response in resectable NSCLC: a reconstructed individual patient data meta-analysisAntonio Nuccio, Fabio Salomone, Alberto Servetto, et al.
Nature Communications|May 16, 2025
Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trialOscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 11, 2023
Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancerErnest Nadal, Martín Oré-Arce, Jordi Remon, et al.
Clinical Lung Cancer|February 4, 2025
Elucidating the Role of EGFRL858R in Brain Metastasis Among Patients With Advanced NSCLC Undergoing TKI TherapyEduardo Rios-Garcia, Alberto Guijosa, Enrique Caballé-Perez, et al.
Cancers|November 25, 2020
Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of BiomarkersXabier Mielgo-Rubio, Virginia Calvo, Javier Luna, et al.
BMC Psychology|November 24, 2020
Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal studyN Nuria Viñolas, Rosario Garcia-Campelo, Margarita Majem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancerPierre Saintigny, Benjamin Besse, Patrice Callard, et al.
JAMA Oncology|June 12, 2020
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung CancerBaptiste Kas, Hugues Talbot, Roberto Ferrara, et al.
Future Oncology (London, England)|December 16, 2021
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancerByoung Chul Cho, Enriqueta Felip, Hidetoshi Hayashi, et al.
Pageof 53